Overview

* Bausch + Lomb ( BLCO ) Q3 rev grows 7% yr/yr

* Adjusted EPS for Q3 beats consensus, reflecting improved operational performance

* Company reports GAAP net loss of $28 mln due to increased tax provisions

Outlook

* Bausch + Lomb ( BLCO ) maintains full-year revenue guidance at $5.050 bln to $5.150 bln

* Company raises lower end of full-year adjusted EBITDA guidance to $870 mln

Result Drivers

* VISION CARE GROWTH - Vision Care segment revenue increased due to strong performance in dry eye portfolio and contact lenses

* PHARMACEUTICALS GROWTH - Pharmaceuticals segment growth driven by increased sales of MIEBO and international expansion

* SURGICAL SEGMENT - Modest growth in Surgical segment due to increased equipment sales and implantables, particularly in premium IOLs

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Meet $1.28 $1.28

Revenue bln bln (10

Analysts

)

Q3 Beat $0.18 $0.17

Adjusted (12

EPS Analysts

)

Q3 EPS -$0.08

Q3 Beat $66 mln $56.30

Adjusted mln (9

Net Analysts

Income )

Q3 Net -$28 mln

Income

Q3 Beat $243 mln $235.80

Adjusted mln (10

EBITDA Analysts

)

Q3 $95 mln

Operatin

g Income

Analyst Coverage

* The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 5 "strong buy" or "buy", 8 "hold" and 1 "sell" or "strong sell"

* The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy."

* Wall Street's median 12-month price target for Bausch + Lomb Corp ( BLCO ) is $15.50, about 1.9% above its October 28 closing price of $15.20

* The stock recently traded at 20 times the next 12-month earnings vs. a P/E of 21 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)